Who makes QL1207H injection?

QL1207H injection is developed by Qilu Pharmaceutical Co., Ltd..

What development phase is QL1207H injection in?

QL1207H injection is in Phase 3.

Last reviewed 2026-04-23 · How we verify

QL1207H injection

Qilu Pharmaceutical Co., Ltd. · Phase 3 active Small molecule

QL1207H injection's mechanism is not publicly available.

At a glance

Generic name	QL1207H injection
Sponsor	Qilu Pharmaceutical Co., Ltd.
Modality	Small molecule
Phase	Phase 3

Mechanism of action

Unfortunately, there is limited information available on the exact mechanism of action of QL1207H injection.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Clinical Study of QL1207H Injection Versus Aflibercept for Neovascular Age-related Macular Degeneration (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

QL1207H injection CI brief — competitive landscape report
QL1207H injection updates RSS · CI watch RSS
Qilu Pharmaceutical Co., Ltd. portfolio CI